RVMD · Revolution Medicines, Inc.
$203.71
+1.71 (+0.85%)
At close · Aug 14
Market Cap
$43.66B
Shares
214.34M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$1.13B
-88.5%
FY2025
Operating Margin
-4207.12%
-3477.1pp
FY2023
Diluted EPS
-$5.95
-66.2%
FY2025
Operating Cash Flow
-$897.74M
-61%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $0 | $11.58M | $35.38M | $29.39M | $42.98M | $50.04M | $20.17M | |
| $1.3B | $987.33M | $592.23M | $423.14M | $253.07M | $186.95M | $132.25M | $91.76M | $51.08M | |
| $330.91M | $195.04M | $97.3M | $75.62M | $40.59M | $30.45M | $21.43M | $12.41M | $9.41M | |
| $303K | $870K | $1.07M | $1.07M | $1.07M | $1.07M | $1.07M | $1.07M | $198K | |
| — | $7.78M | $6.56M | $5.04M | $3.97M | $3.08M | $2.61M | $2.27M | $1.57M | |
| $1.63B | $1.18B | $689.52M | $498.77M | $293.66M | $217.4M | $153.68M | $104.16M | $60.49M | |
| -$1.63B | -$1.18B | -$689.52M | -$487.19M | -$258.28M | -$188.01M | -$110.7M | -$54.12M | -$40.33M | |
| — | — | — | -4207.12% | -730.01% | -639.7% | -257.54% | -108.15% | -200% | |
| — | -$1.17B | -$682.97M | -$482.14M | -$254.31M | -$184.93M | -$108.09M | -$51.85M | -$38.76M | |
| $59.34M | $24.23M | $0 | $0 | $0 | $12K | $71K | $106K | $116K | |
| $98.46M | $90.69M | $86.88M | $47.48M | $9.15M | $929K | $2.24M | $2.19M | $777K | |
| -$141.04M | $51.07M | $88.68M | $47.29M | $9.15M | $917K | $2.17M | $2.08M | -$1.46M | |
| -$1.77B | -$1.13B | -$600.85M | -$439.89M | -$249.13M | -$187.09M | -$108.53M | -$52.04M | -$41.79M | |
| — | $0 | -$753K | -$3.52M | -$420K | $0 | -$371K | -$4.37M | — | |
| -$1.77B | -$1.13B | -$600.09M | -$436.37M | -$248.71M | -$187.09M | -$108.16M | -$47.66M | -$41.79M | |
| — | — | — | -3768.28% | -702.95% | -636.58% | -251.63% | -95.25% | -207.24% | |
| -$1.77B | -$1.13B | -$600.09M | -$436.37M | -$248.71M | -$187.09M | -$110.38M | -$61.9M | -$48.82M | |
| -$1.78B | -$1.13B | -$599.32M | -$434.04M | -$250.11M | -$187.58M | -$108.12M | -$47.59M | -$41.79M | |
| USD/shares | — | -$5.95 | -$3.58 | -$3.86 | -$3.08 | -$2.57 | -$2.01 | — | — |
| USD/shares | — | -$5.95 | -$3.58 | -$3.86 | -$3.08 | -$2.57 | -$2.01 | — | — |
| shares | — | 190.13M | 167.74M | 113.15M | 80.63M | 72.81M | 54.87M | 2.77M | 2.3M |
| shares | — | 190.13M | 167.74M | 113.15M | 80.63M | 72.81M | 54.87M | 2.77M | 2.3M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 14.24×
EV/EBIT
—
Peer median 34.60×
P/E (TTM)
—
Peer median 29.46×
Peer medians compare against the 59 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Collaboration Revenue | $35,380,000 | $29,390,000 | $42,983,000 | $50,041,000 |
Key facts
CIK
1628171
CUSIP
76155X100
13F (30d)
642 filings
634 filers
Visit website
Investor relations